2023-04-26 15:00:00
Once, twice, three times: even if it means annoying, the European Commission has repeatedly postponed the presentation of its long-awaited “pharmaceutical package”. Finally, on Wednesday 26 April, she launched herself, despite pressure from powerful sector lobbies, and lifted the veil on her ambitions: to make EU pharmaceutical legislation “softer, more flexible and more adapted to the needs of citizens and businesses. To achieve this, two tools are proposed: a draft directive and a draft regulation which, together, intend in particular to tackle shortages by better coordinating the stocks of medicines deemed “critical”.
“The Covid-19 pandemic has in particular highlighted the shortcomings of the current legal framework, which have negative repercussions on patients, health systems and health professionals”, notes the European Commission. The institution puts forward a track which should, according to it, make it possible to “remedy systemic shortages at all times”: that of better monitoring the markets.
[…]
This article is reserved for our L’Usine Nouvelle subscribers
Support expert journalism.
Login
VOS INDICES
source
Selected for you
1682543448
#pharmaceutical #legislation #tackle #drug #shortages
